INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: https://www.ijpsjournal.com

OPEN ACCESS

Review Article

Artificial Intelligence in Pharmaceutical Preformulation and Stability: A Paradigm Shift

Siddhi Gurav*, Dr. Sunita Ogale, Ruchita Dhangar

VIVA Institute of Pharmacy, Virar (E).

ARTICLE INFO

Published: 24 June 2025
Keywords:
Artificial intelligence, machine learning, drug stability, preformulation studies, ICH guidelines, predictive modelling, pharmaceutical development
DOI:
10.5281/zenodo.15730388

ABSTRACT

The integration of artificial intelligence (AI) and machine learning (ML) into pharmaceutical sciences has significantly transformed traditional approaches in preformulation and stability assessment. Historically reliant on empirical and time-intensive methodologies, pharmaceutical development is now benefitting from data-driven models that accelerate formulation design, improve precision, and reduce development time. This review explores critical innovations including solubility prediction using machine learning algorithms, AI-supported polymorph identification, and computational modeling for drug stability forecasting aligned with ICH Q1A(R2) guidelines. Through real-world case studies, we discuss the profound impact of these tools on reducing post-market formulation failures, optimizing bioavailability, and supporting regulatory compliance. Challenges such as data transparency, model validation, and regulatory adaptation are addressed. Ultimately, the convergence of AI with pharmacokinetic modeling is ushering in an era of patient-centric, robust, and efficient drug development.

INTRODUCTION

Pharmaceutical formulation relies heavily on preformulation and stability studies, which lay the groundwork for ensuring a drug's safety, efficacy, and manufacturability. With the complexity of modern therapeutics, traditional trial-and-error methods are proving inefficient. AI has emerged as a powerful tool capable of modeling intricate variables and predicting formulation outcomes with greater accuracy and speed. By utilizing large datasets and algorithmic precision, AI is revolutionizing how formulations are developed, evaluated, and optimized.[1]

2. Preformulation Science and the Role of Predictive Models

2.1 Physicochemical Profiling

***Corresponding Author:** Siddhi Gurav
Address: *VIVA Institute of Pharmacy, Virar (E).*
Email ✉: siddhigurav6789@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Key preformulation parameters such as solubility, particle size, pKa, hygroscopicity, and polymorphism critically influence drug performance. AI-enabled models, particularly those based on machine learning, now enable rapid assessment and prediction of these parameters, reducing reliance on extensive experimental trials.[2]

2.2 Solubility and Bioavailability

Oral bioavailability often hinges on solubility. Algorithms using molecular descriptors can predict solubility with accuracy nearing 90%, guiding early-stage selection and formulation design, especially for poorly soluble compounds.[3,4]

2.3 Polymorph Screening

Polymorphic variation affects dissolution behavior and stability. Deep learning techniques, trained on crystallographic and thermodynamic data, can identify stable polymorphs that meet both pharmacological and regulatory standards.[5]

2.4 Particle Engineering and Flow Behavior

Particle morphology and flow properties are essential for solid dosage forms. Predictive models evaluate these properties to improve blend uniformity and compressibility, ensuring consistent drug release.[6]

2.5 Compatibility and Excipient Selection

Drug-excipient interactions can lead to stability issues or reduced efficacy. AI tools, utilizing compatibility databases, can predict adverse interactions and guide selection towards synergistic excipient combinations.[7]

3. Stability Assessment and Computational Forecasting

3.1 Shelf-Life Prediction

Stability models trained on historical data help forecast degradation kinetics, enabling accurate shelf-life estimation even before full long-term studies are complete.[8]

3.2 Stress Testing and Environmental Sensitivity

Predictive analytics simulate stress conditions (e.g., thermal, photolytic, humidity) to evaluate formulation robustness. This informs packaging design and labeling recommendations.[9]

3.3 Bridging Real-Time and Accelerated Studies

By correlating accelerated testing results with real-time data, AI tools help in early stability determination and reduce risks during post-marketing surveillance.[10]

4. Formulation Design through Pharmacological Modeling

Predictive modeling supports the design of formulations with targeted release profiles. For example, in BCS Class II drugs, AI-enhanced PK/PD modeling has led to a 15–20% improvement in bioavailability forecasts. These tools also assist in designing sustained-release and lipid-based systems, closely aligning in vitro and in vivo performance.[11]

5. AI Models in Pharmaceutical Development

Various AI frameworks are currently employed, including Random Forest and SVMs for solubility and polymorph prediction, Deep Neural Networks for complex property correlation, and SHAP and LIME for interpretability. These tools not only

provide accurate predictions but also enhance confidence in regulatory documentation.[12]



Figure :1

6. Practical Implementations and Industry Case Studies

Major pharmaceutical companies are applying AI in early identification of stable drug candidates, real-time quality monitoring under QbD frameworks, reducing development cycles by up to 50%, and predicting failure modes and mitigating risk pre-commercialization. [13-15]

7. Limitations and Future Directions

Despite the progress, several challenges persist: Data integrity, interpretability, collaborative gaps, and evolving regulatory frameworks. Looking forward, AI holds potential for personalized formulations and real-time adjustments through integration with lab automation systems. Regulatory bodies are also exploring validation frameworks for AI-based evidence submission. [16-18]

CONCLUSION

Artificial intelligence is redefining the pharmaceutical formulation paradigm, offering unprecedented capabilities in predicting solubility, stability, and therapeutic performance. Its integration with pharmacokinetics and regulatory science promotes a more efficient, accurate, and patient-centric drug development process. Embracing these tools responsibly will pave the way for safer, faster, and more cost-effective therapeutics.

REFERENCES

1. Aulton ME, Taylor KM. Aulton's Pharmaceutics: The Design and Manufacture of Medicines. 5th ed. Elsevier; 2017.
2. Witten IH, Frank E, Hall MA, Pal CJ. Data Mining: Practical Machine Learning Tools and Techniques. 4th ed. Elsevier; 2016.
3. Bergström CA, Wassvik CM, Johansson K, Hubatsch I. Molecular pharmaceutics. 2014;11(4):1092–1100.
4. Avdeef A, Berger CM, Brownell C. Drug-excipient compatibility. Eur J Pharm Sci. 2001;13(2):115–122.
5. Cruz-Cabeza AJ, Reutzel-Edens SM. Polymorphism, thermodynamics, and kinetics. Chem Soc Rev. 2015;44(23):8619–8635.
6. Jermain SV, Brough C, Williams RO. Amorphous solid dispersions and particle engineering. Pharm Res. 2018;35(6):125.
7. Avdeef A, Berger CM, Brownell C. Drug-excipient compatibility. Eur J Pharm Sci. 2001;13(2):115–122.
8. Waterman KC, Adami RC. Accelerated aging predictions. Int J Pharm. 2005;293(1–2):101–125.
9. Waterman KC. Understanding and predicting drug product shelf life. J Pharm Sci. 2011;100(10):3887–3897.
10. Waterman KC. Understanding and predicting drug product shelf life. J Pharm Sci. 2011;100(10):3887–3897.
11. Montgomery DC. Design and Analysis of Experiments. 9th ed. John Wiley & Sons; 2017.
12. Ribeiro MT, Singh S, Guestrin C. Model interpretability methods. Proc ACM SIGKDD. 2016:1135–1144.
13. Stokes JM, Yang K, Swanson K, Jin W, Cubillos-Ruiz A, Donghia NM, et al. A deep learning approach to antibiotic discovery. Cell. 2020;180(4):688–702.e13.
14. Wiercioch M, et al. Pharmaceutical applications of AI. Pharmaceutics. 2021;13(10):1571.
15. Yu LX, et al. Regulatory considerations and modeling. Pharm Res. 2014;31(10):2568–2577.
16. Beam AL, Kohane IS. Big data and machine learning in health care. N Engl J Med. 2018;378(4):302–304.
17. Ribeiro MT, Singh S, Guestrin C. Model interpretability methods. Proc ACM SIGKDD. 2016:1135–1144.
18. FDA. Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD). Discussion Paper. 2021.
19. Schneider G. Automating drug discovery. Nat Rev Drug Discov. 2018;17(2):97–113.
20. European Medicines Agency Regulatory Science Strategy to 2025. 2020.
21. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019;25(1):44–56.
22. Schneider G. Automating drug discovery. Nat Rev Drug Discov. 2018;17(2):97–113.
23. European Medicines Agency. Regulatory Science Strategy to 2025. [Internet]. London: EMA; 2020 [cited 2025 Jun 11].
24. Rajput A, Singh N, Sharma A, Sinha RK. Role of artificial intelligence in drug formulation and delivery systems. Curr Pharm Des. 2021;27(28):3014–3021.
25. Badillo R, Batra S, Rempe D. Machine learning in drug development: recent applications and future prospects. Drug Discov Today. 2022;27(5):1312–1324.

HOW TO CITE: Siddhi Gurav*, Dr. Sunita Ogale, Ruchita Dhangar, Artificial Intelligence in Pharmaceutical Preformulation and Stability: A Paradigm Shift, Int. J. of Pharm. Sci., 2025, Vol 3, Issue 6, 3957-3960. https://doi.org/10.5281/zenodo.15730388